Steered by a prestigious Committee, the MedFIT conference programme brings together bright minds to discuss the latest trends in MedTech, diagnostic and digital health, to debate on innovation-driven topics, to foster learning and provoke conversations that matter. International experts will address current industry issues related to collaboration, financing, market access and regulation as well as MedTech digitalisation.
All MedFIT’s attendees will have access to a mix of live and on-demand content during the event. This content will be available for 30 days afterwards. They will also have the opportunity to debate with the speakers via interactive online chats.
11:30 am – 12:30 pm CET
From product-focused to solution-focused: How are MedTech companies reviewing their value proposition?
The increasing digitalisation and consumerisation of healthcare, along with changing reimbursement models and care delivery pathways, have created opportunities to generate value for MedTech not only through the manufacture and sale of products, but also through the development of more holistic and data-driven solutions.
To what extent does this transition affect the way R&D efforts are led and MedTech companies go-to market model? How can the right financial and clinical stakeholders be identified early in the development to generate evidence and demonstrate the value of innovative products and services? To what extent does this influence MedTech companies’ collaboration choices?
Moderator: Daniel Bejoy, Senior Industry Analyst, Healthcare & Life Sciences, Frost & Sullivan
TRACK 1: COLLABORATE TO INNOVATE
Fostering new collaborations is key to fuel innovation and support R&D needs in MedTech. As global healthcare evolves to deliver more value to patients, partnerships with researchers, hospital leaders, technology experts, payers and innovators are the cornerstone of the medical technologies’ evolution.
1:30 – 2:30 pm CET
Breaking silos: How to incentive interoperability in MedTech and connected health?
Joining the dots of patient data, diagnosis and decision making is the holy grail for connected health. What is standing in the way? Who should drive change? How can further collaboration models lead the way?
2:30 – 3:30 pm CET
Embracing collaborations: The key to successfully designing, scaling and using digital health solutions?
MedTech companies now face the challenge of designing user-friendly digital products and services while supporting their adoption and use by clinicians, healthcare professionals and patients. How do collaborations and partnerships with existing and emerging players, academia and innovative start-ups help to build digital capabilities and secure the deployment of digital medical technologies? How to best ensure that connected devices are intuitive and easy to use? What are the best practices for involving healthcare professionals in the early stages of innovative product development? How to ensure the best training and support for practitioners and develop the necessary skills to optimise the use of technologies?
9:30 – 10:30 am CET
Is your start-up ready to engage with corporate?
What does a start-up need to be ready to collaborate with industry? What are the benefits or constraints to partner with corporate at the early stages of a start-up? On which grounds and what kind of partnerships are set up? How to deal with multiple partners? What are MedTech big players looking for in their strategic partnerships and what can they bring to the development of a young company? What can be the obstacles on the big players part? How to create the win-win scenario to advance technology?
TRACK 2: FINANCING INNOVATION
Seed and Series A investments are crucial to transforming new ideas into products and moving start-up teams into small businesses. Finding the right funding sources and equity partners to get from early stage to regulatory approval is far from straightforward. How to identify the initial sources of funding for MedTech R&D projects? What method should you use to fund your project? How to attract venture for early-stage financing?
9:30 – 10:30 am CET
Investors’ perspective on investing in MedTech post COVID-19
Almost two years later, how has COVID-19 pandemic influenced investors and what is the impact on early-stage pattern of investment? Have some sub-sectors started to become more interesting to private equity firms?
11:30 am – 12:30 pm CET
How to address the right investors as boundaries are blurring between medical devices, diagnostic and digital health technologies?
How have investment strategies evolved with the digitalisation of the MedTech sector? Are traditional MedTech investors diversifying their portfolios? Are there newcomer investors in the field because of digital heath and new opportunities or investments sources? How do early stage MedTech companies continue to attract investment and on what ground?
4:30 – 5:30 pm CET
From seed stage to regulatory approval: How to get your milestones financed?
Developing a roadmap and trying to understand the timing and cost of all potential steps are keys to avoid falling into funding gaps down the road. This means structuring the necessary funds early to achieve specific milestones and subsequent financing rounds to be achieved. How can a young company finance the large expenses prior to regulatory approval? How to identify the right equity partners and involve them in your ongoing operations?
This panel discussion gathering expert investors and successful entrepreneurs aims to provide a better understanding of the timelines, operations, and budgets required to best measure the available funding options at the onset of new start-ups.
Moderator: Arezki Yaiche, Senior France Correspondent M&A/ Antitrust, Freelance & Head of Coverage France & Benelux, Acuris
3:00 – 4:00 pm CET
Which alternative funding options to VCs for biotech & MedTech start-ups?
[Common to BioFIT]
There is more money than ever fuelling the biotech and MedTech industries, and different kind of investors are entering the stage with more influence than previously thought possible. Which options are there? What do you need to identify these funding sources? What are the expectations and specificities of working with angel investors, disease foundations, private equity firms, cross-over funds and family offices? What are the best funding strategies for biotech & MedTech start-ups?
TRACK 3: INNOVATION TO MARKET
Planning a market access should start early in the product development process, increasing the chances of successfully bringing an innovation to market. How to keep track on market trends and regulatory requirements while building your strategy? How to build the right business model? This track aims to give a comprehensive approach of the pathway to market for emerging medical technologies.
3:30 – 4:30 pm CET
From big companies to founder: Hear the stories of executives turned MedTech entrepreneurs
This session will be held as an interview followed by a group discussion, in order to make the most of the speakers’ entrepreneurial background. What motivated their choices when creating a company? What did they gain from their experience in a large MedTech company? What were the obstacles they had not foreseen?
9:30 – 10:30 am CET
Case study: Which business model for digital innovations to manage chronic diseases?
Innovative digital solutions intend to make a difference in addressing chronic conditions. As they include and connect a growing number of devices, apps and services to support patients and their caregivers, what are their actual contribution to chronic illness management? What are the current business models for consumers and payers? How are these solutions adopted by the end users and what is their added value?
11:30 am – 12:30 pm CET
Medical-grade devices vs. consumer-grade devices: How is digitalisation blurring the lines for diagnostic and monitoring solutions?
Evolving consumer expectation and anytime patient data access are making way for non-traditional players to disrupt the healthcare industry. While MedTech and diagnostic sectors have already changed with rising digital medical-grade solutions, what are the challenges additionally brought by the rapid development of consumer-grade devices? How are MedTech players to stay competitive when an increasing number of consumer-level trackers & apps may successfully turn into certified medical devices? Is the reimbursement model the only one that’s right? On which grounds to choose between going over-the-counter or reimbursed for these types of solutions?
- Florian Graillot, Founding Partner, astoryaVC